BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Stock Rated “Moderate Buy” by Wall Street Analysts
Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average […]
13 Oct 07:14 · The Markets Daily